Search results for "multivariate"

showing 10 items of 1520 documents

The Human Biodiversity in the Middle of the Mediterranean. Study of native and settlers populations on the Sicilian context

2020

[IT] Negli ultimi 200.000 anni, la specie umana si è diffusa in tutta la Terra, adattando la sua morfologia e fisiologia a un'ampia gamma di habitat. Lo scheletro umano ha quindi registrato i principali effetti ambientali e di conseguenza i reperti scheletrici assumono grande importanza nell'indagine dei processi evolutivi. Oggi le moderne tecniche di indagini quantitative delle principali caratteristiche morfologiche consentono di metterle in relazione con la variabilità genetica. La posizione geografica della Sicilia, l'isolamento e la sua lunga e dinamica storia di colonizzazione (diversi e numerosi contributi culturali e biologici) hanno creato un contesto peculiare che consente uno stu…

OdontometricsGeometric Moprhometrics Photogrammetry 3D Models Human skulls SicliyRange (biology)PopulationBiodiversityContext (language use)Settore BIO/08 - AntropologiaStatistiche multivariateAntropologia fisicaMorfometria geometricaFotogrametriaGenetic variabilityeducationEvoluzione umanaSicilyHuman evolutioneducation.field_of_studyGeometric morphometricsEvolución humanaMorfometría geométricaHuman migrationbusiness.industryEcologyFotogrammetrialanguage.human_languagePhysical anthropologyMultivariate statisticsGeographyPhotogrammetrylanguageSiciliaEstadísticas multivariadasAntropología físicabusinessMATEMATICA APLICADASicilian
researchProduct

The humoral immune system has a key prognostic impact in node-negative breast cancer.

2008

Abstract Estrogen receptor (ER) expression and proliferative activity are established prognostic factors in breast cancer. In a search for additional prognostic motifs, we analyzed the gene expression patterns of 200 tumors of patients who were not treated by systemic therapy after surgery using a discovery approach. After performing hierarchical cluster analysis, we identified coregulated genes related to the biological process of proliferation, steroid hormone receptor expression, as well as B-cell and T-cell infiltration. We calculated metagenes as a surrogate for all genes contained within a particular cluster and visualized the relative expression in relation to time to metastasis with…

OncologyAdultCancer Researchmedicine.medical_specialtyMultivariate analysisEstrogen receptorBreast NeoplasmsMetastasisCohort StudiesBreast cancerImmune systemInternal medicineMedicineCluster AnalysisHumansAgedCell ProliferationOligonucleotide Array Sequence AnalysisAged 80 and overbusiness.industryProportional hazards modelGene Expression ProfilingHazard ratioCarcinomaMiddle Agedmedicine.diseasePrognosisGene Expression Regulation NeoplasticOncologyNeutrophil InfiltrationLymphatic MetastasisCohortImmunologyAntibody FormationFemaleLymph NodesbusinessGenes NeoplasmCancer research
researchProduct

Clinical assessment of patients with advanced non-small-cell lung cancer eligible for second-line chemotherapy

2010

Purpose: Knowledge of prognostic factors for advanced non-small-cell lung cancer (NSCLC) patients eligible for second-line treatment is scarce. The aim of this study was to assess the prognostic role of a number of routinely collected clinical variables and to provide a summary index to discriminate patients according to probability of survival.Methods: individual data from nine randomised trials of second-line treatment in advanced NSCLC were analysed. Primary end-point was overall survival (OS). Cox model, stratified by trial, was used for multivariate analyses, and a prognostic index was provided and validated according to an internal/external procedure.Results: Out of 1239 patients, 119…

OncologyAdultMaleCancer Researchmedicine.medical_specialtyMultivariate analysisLung NeoplasmsWEEKLY DOCETAXELIRINOTECANCOMBINATION CHEMOTHERAPYAntineoplastic AgentsERLOTINIBPrognostic factorsNSCLCTHERAPYPooled analysisPLUS GEMCITABINEInternal medicineCarcinoma Non-Small-Cell LungAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansStage (cooking)Lung cancerEVERY 3 WEEKSAgedNeoplasm StagingRandomized Controlled Trials as TopicAged 80 and overPerformance statusProportional hazards modelbusiness.industryAge FactorsCombination chemotherapyPHASE-III TRIALMiddle Agedmedicine.diseasePrognosisTreatment OutcomeOncologyMeta-analysisPrognostic scoreCOMPARING DOCETAXELSecond-line treatmentAdenocarcinomaFemalebusinessEpidemiologic MethodsNon-small-cell lung cancerEuropean Journal of Cancer
researchProduct

Association of low-penetrance alleles with male breast cancer risk and clinicopathological characteristics: results from a multicenter study in Italy

2013

It is well-known that male breast cancer (MBC) susceptibility is mainly due to high-penetrance BRCA1/2 mutations. Here, we investigated whether common low-penetrance breast cancer (BC) susceptibility alleles may influence MBC risk in Italian population and whether variant alleles may be associated with specific clinicopathological features of MBCs. In the frame of the Italian Multicenter Study on MBC, we genotyped 413 MBCs and 745 age-matched male controls at 9 SNPs annotating known BC susceptibility loci. By multivariate logistic regression models, we found a significant increased MBC risk for 3 SNPs, in particular, with codominant models, for rs2046210/ESR1 (OR = 1.71; 95 % CI: 1.43–2.05;…

OncologyAdultMaleCancer Researchmedicine.medical_specialtyMultivariate analysisSettore MED/06 - Oncologia MedicaClinicopathological characteristicBRCA1/2; Clinicopathological characteristics; ER/PR status; Low-penetrance breast cancer alleles; Male breast cancer; SNPsSingle-nucleotide polymorphismPolymorphism Single NucleotideER/PR statuBreast Neoplasms MaleBreast cancerBRCA1/2Internal medicineGenotypemedicineHumansGenetic Predisposition to DiseaseAlleleReceptor Fibroblast Growth Factor Type 2Low-penetrance breast cancer alleleAllelesAgedAged 80 and overbusiness.industryEstrogen Receptor alphaHigh Mobility Group Proteinsclinicopathological characteristicsMiddle Agedmedicine.diseasePenetranceMale breast cancerer/pr statusOncologyTOX3ItalyReceptors EstrogenMale breast cancerCase-Control StudiesMultivariate AnalysisTrans-Activatorslow-penetrance breast cancer allelesbusinessApoptosis Regulatory ProteinsReceptors Progesteroneclinicopathological characteristics; er/pr status; male breast cancer; brca1/2; snps; low-penetrance breast cancer allelesSNPs
researchProduct

Cancer stem cell analysis and clinical outcome in patients with glioblastoma multiforme

2008

Abstract Purpose: Cancer stem cells (CSC) are thought to represent the population of tumorigenic cells responsible for tumor development. The stem cell antigen CD133 identifies such a tumorigenic population in a subset of glioblastoma patients. We conducted a prospective study to explore the prognostic potential of CSC analysis in glioblastoma patients. Experimental Design: We investigated the relationship between the in vitro growth potential of glioblastoma CSCs and patient death or disease progression in tumors of 44 consecutive glioblastoma patients treated with complete or partial tumorectomy followed by radiotherapy combined with temozolomide treatment. Moreover, we evaluated by immun…

OncologyAdultMaleCancer Researchmedicine.medical_specialtyPathologyAC133 Antigen; Adult; Aged; Antigens CD; Brain Neoplasms; Female; Glioblastoma; Glycoproteins; Humans; Ki-67 Antigen; Male; Middle Aged; Multivariate Analysis; Neoplastic Stem Cells; Peptides; Prospective Studiesmedicine.medical_treatmentPopulationAntigens CDCancer stem cellInternal medicinemedicineHumansAC133 AntigenProspective StudiesAntigensProspective cohort studyeducationAgedGlycoproteinseducation.field_of_studyTemozolomideSettore MED/08 - ANATOMIA PATOLOGICAbusiness.industryBrain NeoplasmsHazard ratioMiddle AgedGliobastoma MultiformeCDRadiation therapyKi-67 AntigenOncologyMultivariate AnalysisNeoplastic Stem CellsImmunohistochemistryFemaleStem cellbusinessGlioblastomaPeptidesmedicine.drug
researchProduct

Risk assessment of second primary cancer according to histological subtype of non-Hodgkin lymphoma.

2015

Non-Hodgkin lymphoma (NHL) represents a heterogeneous group of diseases that are known to carry a considerable risk of second primary cancer (SPC). However, little attention has been paid to SPC risk assessment according to NHL subtypes. Data from 10 French population-based cancer registries were used to establish a cohort of 7546 patients with a first diagnosis of NHL (eight subtypes) between 1989 and 2004. Standardized incidence ratios (SIRs) of metachronous SPC were estimated. Among the 7546 patients diagnosed with a NHL, the overall SPC risk was 25% higher than that in the reference population (SIR = 1.25, 95% confidence interval 1.15–1.36). In univariate analysis, the SPC risk differed…

OncologyAdultMaleCancer Researchmedicine.medical_specialtyanimal structuresMultivariate analysisAdolescentPopulationRisk AssessmentCohort StudiesYoung Adultimmune system diseaseshemic and lymphatic diseasesInternal medicineEpidemiologymedicineHumansRegistrieseducationChildAgedAged 80 and overUnivariate analysiseducation.field_of_studybusiness.industryIncidence (epidemiology)IncidenceLymphoma Non-HodgkinfungiAge FactorsInfant NewbornCancerInfantNeoplasms Second PrimaryHematologyMiddle Agedmedicine.diseaseOncologyChild PreschoolPopulation SurveillanceCohortImmunologyFemaleFranceRisk assessmentbusinessFollow-Up StudiesLeukemialymphoma
researchProduct

Tissue factor and its procoagulant activity on cancer‐associated thromboembolism in pancreatic cancer

2021

Abstract Pancreatic cancer frequently involves cancer‐associated thromboembolism, which is strongly associated with poor prognosis. Tissue factor, a blood coagulation factor largely produced in cancer patients as a component of extracellular vesicles, plays a key role in the incidence of cancer‐associated thromboembolism in patients with pancreatic cancer. However, no prospective studies have been published on the relationship between tissue factor and cancer‐associated thromboembolism or patient clinical characteristics, including recent chemotherapy regimens. Thus, we aimed to address this in a Japanese cohort of 197 patients and 41 healthy volunteers. Plasma tissue factor levels were mea…

OncologyAdultMaleRiskCancer Researchmedicine.medical_specialtyEnzyme-Linked Immunosorbent AssayThromboplastinCohort StudiesTissue factorExtracellular VesiclesJapanClinical ResearchPredictive Value of TestsPancreatic cancerInternal medicineThromboembolismmedicineConfidence IntervalsHumansRisk factorProspective cohort studyAgedAged 80 and overbusiness.industryCancerpancreatic neoplasmGeneral MedicineExtracellular vesicleOriginal ArticlesVenous ThromboembolismMiddle Agedmedicine.diseasetissue factorPancreatic NeoplasmsOncologyrisk factorRelative riskCase-Control StudiesCohortMultivariate AnalysisOriginal ArticleFemaleextracellular vesiclebusinessCancer Science
researchProduct

Risk of new or recurrent cancer under immunosuppressive therapy in patients with IBD and previous cancer.

2013

International audience; OBJECTIVE: To explore the risk of new or recurrent cancer among patients with IBD and previous cancer, exposed or not to immunosuppressants. DESIGN: Among the 17 047 patients of the CESAME prospective observational cohort who were enrolled from May 2004 to June 2005, and followed-up until December 2007, we identified 405 patients with cancer diagnosed previous to study entry. We calculated the rates of incident cancer in patients with or without previous cancer, and we assessed by survival analysis and nested case-control study the impact of immunosuppressants on the risk of incident new or recurrent cancer in patients with previous cancer. RESULTS: The rate of incid…

OncologyAdultMalemedicine.medical_specialtyAzathioprineKaplan-Meier EstimateCrohn Disease[ CHIM.ORGA ] Chemical Sciences/Organic chemistryRisk FactorsInternal medicineNeoplasmsEpidemiology of cancermedicineHumansProspective StudiesSurvival analysisAgedProportional Hazards ModelsCrohn's diseasebusiness.industry[CHIM.ORGA]Chemical Sciences/Organic chemistryIncidence (epidemiology)IncidenceGastroenterologyCancerMiddle Agedmedicine.diseaseUlcerative colitis3. Good healthSurgeryCase-Control StudiesCohortMultivariate AnalysisColitis UlcerativeFemaleNeoplasm Recurrence LocalbusinessImmunosuppressive Agentsmedicine.drugFollow-Up Studies
researchProduct

Validation of the revised international prognostic scoring system (IPSS-R) in patients with myelodysplastic syndrome: a multicenter study.

2013

The revised IPSS (IPSS-R) was developed aiming at a better prognostication, taking into account patients treated with best supportive care. We herein validated this model on the basis of data from 1314 patients who received BSC only as well as patients who underwent induction chemotherapy (n=214) or allogeneic transplantation (n=167). We could demonstrate a clear distinction of the IPSS-R risk categories with regard to survival and risk of AML evolution in all patient cohorts. When comparing IPSS-R, IPSS, WHO prognostic scoring system (WPSS) and Duesseldorf score, the best results regarding the ability to predict survival were obtained by the IPSS-R.

OncologyAdultMalemedicine.medical_specialtyPediatricsCancer ResearchScoring systemAllogeneic transplantationSurvivalAdolescenturologic and male genital diseasesRisk AssessmentIPSS; IPSS-R; MDS; Prognosis; Survival; WPSS; Hematology; Oncology; Cancer ResearchRisk categoryYoung AdultRisk FactorsInternal medicinemedicineMDSHumansIn patientAgedAged 80 and overIPSS-Rbusiness.industryIPSSInduction chemotherapyReproducibility of ResultsHematologyMiddle AgedPrognosisSurvival AnalysisMulticenter studyOncologyInternational Prognostic Scoring SystemLeukemia MyeloidMyelodysplastic SyndromesAcute DiseaseMultivariate AnalysisDisease ProgressionWPSSFemalebusinessLeukemia research
researchProduct

Impact of trastuzumab treatment beyond disease progression for advanced/metastatic breast cancer on survival - results from a prospective, observatio…

2013

Abstract Objectives Evidence suggests that continued trastuzumab therapy beyond progression (TBP) may provide additional survival benefit. Within the framework of an observational prospective study of patients with advanced/metastatic breast cancer receiving trastuzumab in routine clinical practice, we had the opportunity to examine the effect of TBP in a large population. Patients and methods Among a total of 1843 trastuzumab-treated patients, a sub-cohort of 418 fulfilled the selection criteria for the TBP analysis: 261 continued trastuzumab and 157 discontinued. Logrank tests and Cox models were used to compare survival and identify prognostic factors. Results Survival from progression w…

OncologyAdultPrognostic variablemedicine.medical_specialtyMultivariate analysisAntineoplastic AgentsBreast NeoplasmsAntibodies Monoclonal HumanizedBreast cancerTrastuzumabInternal medicineGermanymedicineHumansProspective StudiesNeoplasm MetastasisProspective cohort studyAgedAged 80 and overProportional hazards modelbusiness.industryGeneral MedicineMiddle AgedTrastuzumabmedicine.diseaseMetastatic breast cancerSurvival AnalysisSurgeryTreatment OutcomeConcomitantDisease ProgressionSurgeryFemalebusinessmedicine.drugFollow-Up StudiesBreast (Edinburgh, Scotland)
researchProduct